Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction : Scandinavian Cohort Study. / Ueda, Peter; Wintzell, Viktor; Melbye, Mads; Eliasson, Björn; Söderling, Jonas; Gudbjörnsdottir, Soffia; Hveem, Kristian; Jonasson, Christian; Svanström, Henrik; Hviid, Anders; Pasternak, Björn.
In: Clinical Gastroenterology and Hepatology, 2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction
T2 - Scandinavian Cohort Study
AU - Ueda, Peter
AU - Wintzell, Viktor
AU - Melbye, Mads
AU - Eliasson, Björn
AU - Söderling, Jonas
AU - Gudbjörnsdottir, Soffia
AU - Hveem, Kristian
AU - Jonasson, Christian
AU - Svanström, Henrik
AU - Hviid, Anders
AU - Pasternak, Björn
N1 - Funding Information: Funding Supported by grants from the Swedish Research Council , Dr. Margaretha Nilsson’s Foundation for Medical Research, and Region Stockholm (ALF). Dr Ueda was supported by grants from the Swedish Heart-Lung Foundation , Strategic Research Area Epidemiology programme at Karolinska Institutet, and a Faculty Funded Career Position at Karolinska Institutet . Dr Pasternak was supported by a consolidator investigator grant from Karolinska Institutet. Dr Hviid was supported by a Novo Nordisk Foundation investigator grant. Publisher Copyright: © 2023 AGA Institute
PY - 2024
Y1 - 2024
N2 - Background & Aims: Concerns have been raised that the incretin-based diabetes drugs dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists may increase the risk of intestinal obstruction. We aimed to assess the association between use of DPP4 inhibitors and GLP-1 receptor agonists and the risk of intestinal obstruction. Methods: Using data from nationwide registers in Sweden, Denmark, and Norway, 2013–2021, we conducted 2 cohort studies, one for DPP4 inhibitors and one for GLP-1 receptor agonists, to investigate the risk of intestinal obstruction as compared with an active comparator drug class (sodium-glucose co-transporter 2 [SGLT2] inhibitors). Results: Among 19,0321 new users of DPP4 inhibitors (median (interquartile range [IQR]) follow-up time, 1.3 [0.6–2.6] years) and 139,315 new users of SGLT2 inhibitors (median [IQR] follow-up time, 0.8 [0.4–1.7] years), 919 intestinal obstruction events occurred. Use of DPP4 inhibitors, as compared with SGLT2 inhibitors, was not associated with a statistically significant increase in risk of intestinal obstruction (adjusted incidence rate, 2.0 vs 1.8 per 1000 person-years; hazard ratio, 1.13; 95% confidence interval, 0.96–1.34). Among 121,254 new users of GLP-1 receptor agonists (median [standard deviation] follow-up time, 0.9 [0.4–1.9] years) and 185,027 new users of SGLT2 inhibitors (median [IQR] follow-up time, 0.8 [0.4–1.8] years), 557 intestinal obstruction events occurred. Use of GLP-1 receptor agonists was not associated with a statistically significant increase in risk of intestinal obstruction (adjusted incidence rate, 1.3 vs 1.6 per 1000 person-years; hazard ratio, 0.83; 95% confidence interval, 0.69–1.01). Conclusions: In this analysis of nationwide data from 3 countries, previous safety signals indicating an increased risk of intestinal obstruction with use of DPP4 inhibitors and GLP-1 receptor agonists were not confirmed.
AB - Background & Aims: Concerns have been raised that the incretin-based diabetes drugs dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists may increase the risk of intestinal obstruction. We aimed to assess the association between use of DPP4 inhibitors and GLP-1 receptor agonists and the risk of intestinal obstruction. Methods: Using data from nationwide registers in Sweden, Denmark, and Norway, 2013–2021, we conducted 2 cohort studies, one for DPP4 inhibitors and one for GLP-1 receptor agonists, to investigate the risk of intestinal obstruction as compared with an active comparator drug class (sodium-glucose co-transporter 2 [SGLT2] inhibitors). Results: Among 19,0321 new users of DPP4 inhibitors (median (interquartile range [IQR]) follow-up time, 1.3 [0.6–2.6] years) and 139,315 new users of SGLT2 inhibitors (median [IQR] follow-up time, 0.8 [0.4–1.7] years), 919 intestinal obstruction events occurred. Use of DPP4 inhibitors, as compared with SGLT2 inhibitors, was not associated with a statistically significant increase in risk of intestinal obstruction (adjusted incidence rate, 2.0 vs 1.8 per 1000 person-years; hazard ratio, 1.13; 95% confidence interval, 0.96–1.34). Among 121,254 new users of GLP-1 receptor agonists (median [standard deviation] follow-up time, 0.9 [0.4–1.9] years) and 185,027 new users of SGLT2 inhibitors (median [IQR] follow-up time, 0.8 [0.4–1.8] years), 557 intestinal obstruction events occurred. Use of GLP-1 receptor agonists was not associated with a statistically significant increase in risk of intestinal obstruction (adjusted incidence rate, 1.3 vs 1.6 per 1000 person-years; hazard ratio, 0.83; 95% confidence interval, 0.69–1.01). Conclusions: In this analysis of nationwide data from 3 countries, previous safety signals indicating an increased risk of intestinal obstruction with use of DPP4 inhibitors and GLP-1 receptor agonists were not confirmed.
KW - Adverse Events
KW - Incretin-based Drugs
KW - Type 2 Diabetes
U2 - 10.1016/j.cgh.2023.08.034
DO - 10.1016/j.cgh.2023.08.034
M3 - Journal article
C2 - 37716613
AN - SCOPUS:85178181305
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
SN - 1542-3565
ER -
ID: 388330602